Management's growth story is 11 to 13 points of EPS from selling buildings, and they say it dies after fiscal 24.
Thesis: Reported EPS declines 12-20% and management manufactures 9-12% 'underlying growth' by deleting the headwinds, two of which (sale-leaseback and COVID) are structural and dying. The $1.1B of cash flow comes from cutting $600M of capex and drawing down inventory in stores where shrink is accelerating, while retail comps are -3.3% and the healthcare build only reaches breakeven after burning capital for two years.
Verdict: SHORT — Conviction: MEDIUM
Catalyst: Q1 sequential decline confirmed by the five front-loaded headwinds, then Q2 ramp of the 50 to 60 cent adjusted EPS benefit from cost actions, which shows whether $1B savings drop to the bottom line or get absorbed by reimbursement and shrink.
Key Risk: The $1 billion cost program is already locked in from actions taken in six weeks, and reimbursement pressure is guided lower in fiscal 24. If retail comps stabilize, a short gets run over by genuine cost-driven earnings growth.
The Tell: Unprompted, management volunteered that 'we do not expect any contribution from sale and leaseback beyond fiscal 24' while simultaneously using those gains to frame the fiscal 24 bridge. They told you the tailwind expires and asked you to count it anyway.
Friction Level: HIGH_FRICTION — Whether deleting 11-13 points of sale-leaseback, 10 points of tax, and COVID decline to claim 9-12% underlying growth is a real run-rate or just arithmetic on expired headwinds.
Report not found
The report data is no longer available. Please return to the archive.